AFT Pharmaceutical's multi-billion R&D opportunity
Welcome to HotCopper’s latest Watchlist, where we’ve been joined by AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson to discuss its expanding global reach and the @tentative” FDA approval the company has just hauled i...
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| RFP | Ann:Notice of Initial Substantial Holder | 22/03/18 | 0 | 111 | |||
|
|||||||
| RFP | Ann:Ceasing to be a Substantial Holder | 20/03/18 | 0 | 103 | |||
|
|||||||
| RFP | Ann:Distribution Quarter ending 31 March 2018 | 01/03/18 | 0 | 97 | |||
|
|||||||
| RFP | Ann:RFP 1HFY18 Results Presentation (Price Sensitive) | 28/02/18 | 1 | 145 | |||
|
|||||||
| RFP | Ann:Appendix 3 (Price Sensitive) | 28/02/18 | 0 | 71 | |||
|
|||||||
| RFP | Ann:RFP 1HFY18 Financial Statements (Price Sensitive) | 28/02/18 | 0 | 75 | |||
|
|||||||
See All Discussions
NSX News